Condition
Type 2 Diabetes Mellitus
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 1,865 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownA Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal ImpairmentNCT07807059 · 2026-09-09
RECRUITINGA Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT07743450 · 2026-08-28
RECRUITINGBody Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 DiabetesNCT07835360 · 2026-07-10
RECRUITINGA Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinNCT07664553 · 2026-07-08
RECRUITINGA Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213 · 2026-07-06
RECRUITINGA Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinNCT07662135 · 2026-07-06
RECRUITINGA Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusNCT07662044 · 2026-07-06
RECRUITINGA Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109 · 2026-07-06
RECRUITINGAn Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk ScoreNCT07554469 · 2026-05-26
RECRUITINGStudy to Evaluate HM15275 in Subjects With Type 2 Diabetes MellitusNCT07527650 · 2026-05-18
RECRUITINGEfficacy of the Omnipod® 6 System Compared With the Omnipod® 5 SystemNCT07579702 · 2026-05-13
RECRUITINGEvaluation of the Fully Closed Loop Omnipod® System in Type 2 DiabetesNCT07521475 · 2026-04-30
RECRUITINGA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23
RECRUITINGPOLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.NCT07433192 · 2026-03-02
RECRUITINGCarotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes MellitusNCT07373938 · 2026-01-25
RECRUITINGAn Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South KoreaNCT07232537 · 2025-11-20
RECRUITINGThe GRoceries Aimed at Increasing Nutrition StudyNCT07167004 · 2025-10-14
RECRUITINGClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes MellitusNCT06704672 · 2025-04-14
RECRUITINGAntidiabetic Effect of Olive Pomace OilNCT06723886 · 2025-01-15
RECRUITINGEfficacy and Safety of Madalena Association in the Treatment of Type II Diabetes MellitusNCT04670666 · 2024-11-18
RECRUITINGCurrent Status of Islet Alpha Cell Function in Patients with Type 2 DiabetesNCT06825182 · 2024-11-07
RECRUITINGAutomated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek ProgrammeNCT07658755 · 2024-10-01
RECRUITINGEfficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive ImpairmentNCT07711171 · 2024-08-19
RECRUITINGClinical Management of Cardiovascular Risk Factors in Adult Patients: A Before-and-After Interventional StudyNCT07447362 · 2024-07-24
RECRUITINGAn Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world ConditionsNCT06278207 · 2024-05-15
RECRUITINGInvestigation of the Effect of Date Consumption on Hedonic Hunger and Appetite in Adult Individuals With Type 2 DiabetesNCT06826235 · 2024-05-14
RECRUITINGEffect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and ControlsNCT06277466 · 2024-01-01
RECRUITINGRadiomics of Intra-abdominal and Subcutaneous Adipose Tissue Predict the Efficacy of Bariatric Surgery (RISABS)NCT06169033 · 2024-01-01
RECRUITINGAssociation of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DMNCT06256419 · 2024-01-01
RECRUITINGEvaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney DiseaseNCT06838416 · 2023-11-17
RECRUITINGA Study of Glycemic Control in Left Ventricular AssistNCT05933161 · 2023-11-10
RECRUITINGPrevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan AfricaNCT05881447 · 2023-06-21
RECRUITINGLiver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)NCT07083336 · 2022-06-05
RECRUITINGEffects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 DiabetesNCT05553093 · 2022-03-15
RECRUITINGPuberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)NCT05008276 · 2021-09-27
RECRUITINGNanshan Elderly Cohort StudyNCT03569735 · 2018-05-26
RECRUITINGChina Diabetes Registry by Metabolic Management CenterNCT03811470 · 2017-05-31
RECRUITINGNon-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes MellitusNCT05697991 · 2015-03-23
RECRUITINGTesting a Diabetes Care Program in Rural and Low-Income ClinicsNCT07538505 · 2027-03-01
NOT_YET_RECRUITINGDiabetes Distress, Medication Adherence Barriers, Self-Management, and Glycemic Control in Adults With Type 2 DiabetesNCT07861308 · 2026-12-15
NOT_YET_RECRUITINGClinical Predictors and Therapeutic Gaps in CKM Syndrome Among Adults With Type 2 DiabetesNCT07854990 · 2026-10-20
NOT_YET_RECRUITINGSoluble TREM-1 in Diabetes-Associated Cardiovascular ComplicationsNCT07847112 · 2026-10-01
NOT_YET_RECRUITINGPlatelet Indices and Blood Groups in Type 2 Diabetes Vascular ComplicationsNCT07847099 · 2026-09-26
NOT_YET_RECRUITINGContinued Access to the Endogenex System for Participants in the ReCET Pivotal StudyNCT07197788 · 2026-09-01
ENROLLING_BY_INVITATIONIncretin Therapy and Exercise in Type 2 DiabetesNCT07833813 · 2026-09-01
NOT_YET_RECRUITINGIntegrated Diabetes and Oral Health Care in OmanNCT07809477 · 2026-09-01
NOT_YET_RECRUITINGGlycemic Velocity and Early Retinal Microvascular Change With GLP-1RA Versus SGLT2i Initiation in Type 2 Diabetes (GLIDE)NCT07723820 · 2026-09-01
NOT_YET_RECRUITINGSystemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney DiseaseNCT07773467 · 2026-09-01
NOT_YET_RECRUITINGEfficacy and Safety of Hebenrun in Patients With Type 2 DiabetesNCT07768280 · 2026-09-01
NOT_YET_RECRUITINGA Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 DiabetesNCT07755150 · 2026-08-30
NOT_YET_RECRUITING"Ultrasound-Enhanced Propolis Therapy for Healing Diabetic Foot Wounds"NCT07099482 · 2026-08-30
NOT_YET_RECRUITINGHuangqi Gegen Decoction for Endothelial Function in Type 2 Diabetes at Very High ASCVD RiskNCT07775664 · 2026-08-04
ACTIVE_NOT_RECRUITINGThe Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral NeuropathyNCT07757399 · 2026-08-01
NOT_YET_RECRUITINGEvaluating the Effectiveness of a Smart Screening and Tiered Management Tool for Diabetic Kidney Disease in Primary Care: A Cluster Randomized TrialNCT07707518 · 2026-07-30
NOT_YET_RECRUITINGFinerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor AnalysisNCT07717697 · 2026-07-30
NOT_YET_RECRUITINGVitamin D Status and Lipid Profile in Obese Adults With Type 2 DiabetesNCT07729553 · 2026-07-25
NOT_YET_RECRUITINGEffect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular DiseaseNCT07704190 · 2026-07-15
NOT_YET_RECRUITINGLLM-Assisted Diabetes and Hypertension Management by Village DoctorsNCT07678658 · 2026-07-01
NOT_YET_RECRUITINGULTRASONOGRAPHIC EVALUATION OF TALAR CARTILAGE THICKNESS IN PATIENTS WITH DIABETIC POLYNEUROPATHYNCT07801131 · 2026-06-19
COMPLETEDResveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 DiabetesNCT07569744 · 2026-05-01
COMPLETEDCommon interventions
PlaceboDRUG324MetforminDRUG150SitagliptinDRUG72GlimepirideDRUG39Insulin GlargineDRUG38DapagliflozinDRUG37PioglitazoneDRUG35ExenatideDRUG34PlaceboOTHER28LiraglutideDRUG24SaxagliptinDRUG22VildagliptinDRUG21insulinDRUG20ipragliflozinDRUG17AcarboseDRUG16Sitagliptin phosphateDRUG15Comparator: PlaceboDRUG14RosiglitazoneDRUG14DulaglutideDRUG13EmpagliflozinDRUG12OmarigliptinDRUG12Sotagliflozin (SAR439954)DRUG12AlogliptinDRUG11Insulin degludecDRUG11Lixisenatide (AVE0010)DRUG11
Leading sponsors
Trial status mix
COMPLETED1,428
UNKNOWN213
TERMINATED99
RECRUITING38
NOT_YET_RECRUITING28
ACTIVE_NOT_RECRUITING26
WITHDRAWN24
SUSPENDED5
ENROLLING_BY_INVITATION3
NO_LONGER_AVAILABLE1
Phase mix
NA502
PHASE3364
PHASE1280
PHASE4277
PHASE2249
EARLY_PHASE115
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.